Multi‑omics analysis identifies different molecular subtypes with unique outcomes in early-stage poorly differentiated lung adenocarcinoma.

ABSTRACT:

Introduction

Early-stage poorly differentiated lung adenocarcinoma (LUAD) is plagued by a high risk of postoperative recurrence, and its prognostic heterogeneity complicates treatment and surveillance planning. We conducted this integrative multi-omics study to identify those patients with a truly high risk of adverse outcomes.

Methods

Whole-exome, RNA and whole methylome sequencing were carried out on 101 treatment-naïve early-stage poorly differentiated LUADs. Integrated analyses were conducted to disclose molecular characteristics and explore molecular subtyping. Functional validation of key molecules was carried out through in vitro and in vivo experiments.

Results

Recurrent tumors exhibited significantly higher ploidy (p = 0.024), the fraction of the genome alter

SUBMITTER: Liu B 

PROVIDER: S-EPMC12044723 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature